For smaller biotech companies, the new Section 232 tariff is more than an added cost - it adds uncertainty at exactly the wrong time. With tariffs now in effect, companies already operating with limited resources are facing higher costs, scarce capital, and unanswered questions about how to navigate the new rules. For early-stage programs, those pressures can influence critical decisions about what gets advanced - and what doesn’t. More in @statnews: https://www.statnews.com/2026/10/08/trump-tariffs-section-232-imported-prescription-drugs-challenge-biotech-companies/